Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain

International Journal of Neuropsychopharmacology

Volumn 16, Issue 7, 2013, Pages 1577-1586

  Nord, Magdalena ^a   Finnema, Sjoerd J ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C AZ10419369; escitalopram; PET

Indexed keywords

AZ 10419369; AZ 10419369 C 11; ESCITALOPRAM; RADIOISOTOPE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HAPLORHINI; HEADACHE; HUMAN; MESENCEPHALON; NAUSEA; NONHUMAN; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; RAPHE NUCLEUS; SINGLE DRUG DOSE; TEMPORAL CORTEX; THALAMUS;

ADULT; ANIMALS; BENZOPYRANS; BRAIN; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MORPHOLINES; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; YOUNG ADULT;

EID: 84880562306     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001617     Document Type: Article

References (39)

1. Bel N, Artigas F (1992) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei : an in vivo microdialysis study. Eur J Pharmacol 229:101-103.
2. Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245.
3. Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55-68.
4. Bergstrom M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L (1981) Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 5 :136-141.
5. Breaud AR, Harlan R, Kozak M, Clarke W (2009) A rapid and reliable method for the quantitation of tricyclic antidepressants in serum using HPLC-MS/MS. Clin Biochem 42:1300-1307.
6. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, Zimmer L, Costes N, Mulligan R, Reutens D (2006) Increased serotonin receptor availability in human sleep : evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage 30:341-348.
7. Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, Farde L (2010) Fenfluramine-induced serotonin release decreases [(11)C]AZ10419369 binding to 5-HT(1B)- receptors in the primate brain. Synapse 64:573-577.
8. Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L (2012) Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab 32:685-695.
9. Fuller RW (1994) Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55:163-167.
10. Hervas I, Artigas F (1998) Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol 358:9-18.
11. Innis RB et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
12. Invernizzi R, Belli S, Samanin R (1992) Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584:322-324.
13. Invernizzi R, Bramante M, Samanin R (1994) Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur J Pharmacol 260:243-246.
14. Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL (2006) A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 148:185-193.
15. Juan H, Zhiling Z, Huande L (2005) Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). J Chromatogr B Analyt Technol Biomed Life Sci 820:33-39.
16. Kirchherr H, Kuhn-Velten WN (2006) Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 843:100-113.
17. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques : A critical review. J Cereb Blood Flow Metab 20:423-451.
18. Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L (2007) PET measurement of serotonin transporter occupancy: A comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 10:777-785.
19. Maier DL, Sobotka-Briner C, Ding M, Powell ME, Jiang Q, Hill G, Heys JR, Elmore CS, Pierson ME, Mrzljak L (2009) [N-methyl- 3H3]AZ10419369 binding to the 5-HT1B receptor : in vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther 330:342-351.
20. Meltzer H (1989) Serotonergic dysfunction in depression. Br J Psychiatry 155(Suppl. 8) :25-31.
21. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835.
22. Michelsen KA, Prickaerts J, Steinbusch HW (2008) The dorsal raphe nucleus and serotonin : implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 172:233-264.
23. Milak MS, Severance AJ, Prabhakaran J, Kumar JS, Majo VJ, Ogden RT, Mann JJ, Parsey RV (2011) In vivo serotoninsensitive binding of [11C]CUMI-101 : A serotonin 1A receptor agonist positron emission tomography radiotracer. J Cereb Blood Flow Metab 31:243-249.
24. Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288-295.
25. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 30:1682-1706.
26. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, Takano A, Karlsson P, Gulyas B, Medd AM, Lee CM, Powell ME, Heys JR, Potts W, Seneca N, Mrzljak L, Farde L, Halldin C (2008) [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 41:1075-1085.
27. Pineyro G, Blier P (1999) Autoregulation of serotonin neurons : role in antidepressant drug action. Pharmacol Rev 51:533-591.
28. Reis M, Cherma MD, Carlsson B, Bengtsson F (2007) Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 29:758-766.
29. Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl. 1) :2-19.
30. Ridler K, Plisson C, Rabiner EA, Gunn RN, Easwaramoorthy B, Abi-Dargham A, Laruelle M, Slifstein M (2011) Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis. Synapse 65:1119-1127.
31. Romero L, Artigas F (1997) Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem 68:2593-2603.
32. Romero L, Bel N, Artigas F, de Montigny C, Blier P (1996) Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors : in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15:349-360.
33. Sari Y (2004) Serotonin1B receptors : from protein to physiological function and behavior. Neurosci Biobehav Rev 28:565-582.
34. Schain M, Toth M, Cselenyi Z, Stenkrona P, Halldin C, Farde L, Varrone A (2012) Quantification of serotonin transporter availability with [11C]MADAM-a comparison between the ECAT HRRT and HR systems. Neuroimage 60:800-807.
35. Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, McGuire P, Cowen PJ, Howes O (2012) Measuring endogenous changes in serotonergic neurotransmission in humans: A [(11)C]CUMI-101 PET challenge study. Mol Psychiatry 17:1254-1260.
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.) : The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20) :22-33;quiz 34-57.
37. Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, Andersson J, McCarthy D, Smith M, Pierson ME, Soderstrom J, Farde L (2011) Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab 31:113-123.
38. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L (2009) Advancement in PET quantification using 3D-OPOSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36:1639-1650.
39. Varrone A, Stepanov V, Nakao R, Toth M, Gulyas B, Emond P, Deloye JB, Vercouillie J, Stabin MG, Jonsson C, Guilloteau D, Halldin C (2011) Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. J Nucl Med 52:1313-1321.